Clinical trial of the cyclic imide 1-(morpholinomethyl)-4-phtalimido-piperidindione-2,6 (CG 603) in advanced breast cancer.
D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007094:Imides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D008593:Menopause; D009025:Morpholines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D009325:Nausea / Q000139:chemically induced; D010880:Piperidines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D012075:Remission, Spontaneous; D014839:Vomiting / Q000139:chemically induced
D000970:Antineoplastic Agents; D007094:Imides; D009025:Morpholines; D010880:Piperidines; C001848:1-(morpholinomethyl)-4-phthalimidopiperidine-2,6- dione